RT Journal Article
SR Electronic
T1 CD133(+)HIF-1α(−) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2033
OP 2043
DO 10.21873/anticanres.15684
VO 42
IS 4
A1 TACHIKAWA, YUICHI
A1 KAWAI, KAZUSHIGE
A1 OZAKI, KOSUKE
A1 NOZAWA, HIROAKI
A1 SASAKI, KAZUHITO
A1 MURONO, KOJI
A1 EMOTO, SHIGENOBU
A1 KISHIKAWA, JUNKO
A1 YOKOYAMA, YUICHIRO
A1 ABE, SHINYA
A1 NAGAI, YUZO
A1 ANZAI, HIROYUKI
A1 SONODA, HIROFUMI
A1 ISHIHARA, SOICHIRO
YR 2022
UL http://ar.iiarjournals.org/content/42/4/2033.abstract
AB Background/Aim: CD133 and hypoxia-inducible factor 1α (HIF-1α) have been reported to be affected by chemoradiotherapy (CRT), but the combinatorial assessment of these markers for prognosis after CRT has not been fully investigated. Therefore, we aimed to predict recurrence and prognosis in patients with rectal cancer by assessing changes in the expression of both CD133 and HIF-1α after CRT. Materials and Methods: CD133 and HIF-1α expression was evaluated by immunohistochemistry in surgical specimens from 243 patients with advanced low rectal cancer who received CRT followed by curative resection. Results: The positivity rate of CD133 expression showed increase with increased HIF-1α expression. The combination of these two markers showed that the CD133(+)HIF-1α(−) group exhibited a markedly shorter relapse-free survival (p=0.007), higher liver recurrence (p=0.004), and higher local recurrence (p=0.006). Conclusion: CD133(+)HIF-1α(−) expression after CRT is a promising marker to predict recurrence in rectal cancer.